Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers

Simon Chang; Jon J. Rasmussen; Mikkel N. Frandsen; Morten Schou; Marie L. Johansen; Jens Faber; Anna-Marie B. Münster; Johannes J. Sidelmann; Caroline Kistorp

doi:10.1055/s-0038-1636540

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(04): 647-653
DOI: 10.1055/s-0038-1636540

Coagulation and Fibrinolysis

Schattauer GmbH Stuttgart

Procoagulant State in Current and Former Anabolic Androgenic Steroid Abusers

Simon Chang^*

¹Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark

²Department of Clinical Biochemistry, Hospital of South West Jutland, Esbjerg, Denmark

,

Jon J. Rasmussen^*

³Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals, Herlev and Gentofte, Denmark

⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

,

Mikkel N. Frandsen

³Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals, Herlev and Gentofte, Denmark

,

Morten Schou

⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁵Department of Cardiology, Copenhagen University Hospitals, Herlev and Gentofte, Denmark

,

Marie L. Johansen

³Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals, Herlev and Gentofte, Denmark

⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

,

Jens Faber

³Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals, Herlev and Gentofte, Denmark

⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

,

Anna-Marie B. Münster

¹Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark

²Department of Clinical Biochemistry, Hospital of South West Jutland, Esbjerg, Denmark

,

Johannes J. Sidelmann

¹Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark

²Department of Clinical Biochemistry, Hospital of South West Jutland, Esbjerg, Denmark

,

Caroline Kistorp

³Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals, Herlev and Gentofte, Denmark

⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

› Author Affiliations

Abstract

Background Anabolic androgenic steroid (AAS) abusers are considered at increased risk of cardiovascular morbidity and mortality. We hypothesized that current and former AAS abuse would induce a procoagulant shift in the haemostatic balance.

Methods Men 18 to 50 years of age were included as current AAS abusers, former AAS abusers or controls. Morning blood samples were collected after overnight fasting. Thrombin generation (lag time, time to peak, peak height, and endogenous thrombin potential [ETP]) and coagulation factor II (prothrombin), VII and X, antithrombin, protein C, free protein S and tissue factor pathway inhibitor (TFPI) were assessed. Groups were compared by ANOVA or Kruskal–Wallis test and probabilities were corrected for multiple comparisons. Associations were evaluated using linear regression models.

Results ETP was increased around 15% in current (n = 37) and former (n = 33) AAS abusers compared with controls (n = 30; p < 0.001). Prothrombin and factor X were increased ≥10% in AAS abusers and prothrombin was a predictor of ETP (p < 0.0005). Lag time and time to peak were increased 10 to 30% in current AAS abusers (p < 0.001) and associated with higher concentrations of TFPI, antithrombin, protein C and protein S (p < 0.0005; = 0.005). Multivariate linear regression, with all coagulation inhibitors as covariates, identified TFPI to be independently associated with lag time and time to peak (p < 0.0005).

Conclusion Thrombin generation is augmented in current and former AAS abusers, reflecting a procoagulant state, with altered concentrations of coagulation proteins. Prospective studies are needed to clarify whether these findings translate into an increased thrombotic risk in AAS abusers potentially even after cessation.

Keywords

testosterone - substance-related disorders - thrombin - blood coagulation

Full Text

References

References
1 Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014; 24 (05) 383-398
2 Pope Jr HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict 2014; 23 (04) 371-377
3 Baggish AL, Weiner RB, Kanayama G. , et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation 2017; 135 (21) 1991-2002
4 Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med 2012; 42 (02) 119-134
5 La Gerche A, Brosnan MJ. Cardiovascular effects of performance-enhancing drugs. Circulation 2017; 135 (01) 89-99
6 Lippi G, Banfi G. Doping and thrombosis in sports. Semin Thromb Hemost 2011; 37 (08) 918-928
7 Thiblin I, Garmo H, Garle M. , et al. Anabolic steroids and cardiovascular risk: a national population-based cohort study. Drug Alcohol Depend 2015; 152: 87-92
8 Ansell JE, Tiarks C, Fairchild VK. Coagulation abnormalities associated with the use of anabolic steroids. Am Heart J 1993; 125 (2, Pt 1): 367-371
9 Kluft C, Preston FE, Malia RG. , et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost 1984; 51 (02) 157-164
10 Kahn NN, Sinha AK, Spungen AM, Bauman WA. Effects of oxandrolone, an anabolic steroid, on hemostasis. Am J Hematol 2006; 81 (02) 95-100
11 Walker ID, Davidson JF, Young P, Conkie JA. Effect of anabolic steroids on plasma antithrombin III: alpha2 macroglobulin and alpha1 antitrypsin levels. Thromb Diath Haemorrh 1975; 34 (01) 106-114
12 Thorisdottir H, Evans JA, Schwartz HJ, Comp P, Haluschak J, Ratnoff OD. Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy. J Lab Clin Med 1992; 119 (06) 698-701
13 Lowe GD, Thomson JE, Reavey MM, Forbes CD, Prentice CR. Mesterolone: thrombosis during treatment, and a study of its prothrombotic effects. Br J Clin Pharmacol 1979; 7 (01) 107-109
14 Vanberg P, Atar D. Androgenic anabolic steroid abuse and the cardiovascular system. Handb Exp Pharmacol 2010; (195) 411-457
15 Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49 (04) 282-288
16 Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned?. Blood Rev 2012; 26 (05) 197-203
17 Ten Cate H, Hemker HC. Thrombin generation and atherothrombosis: what does the evidence indicate?. J Am Heart Assoc 2016; 5 (08) e003553
18 Aziz M, Sidelmann JJ, Wissing ML, Faber J, Skouby SO. Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation. Gynecol Endocrinol 2015; 31 (09) 720-724
19 Glintborg D, Sidelmann JJ, Altinok ML, Mumm H, Andersen M. Increased thrombin generation in women with polycystic ovary syndrome: a pilot study on the effect of metformin and oral contraceptives. Metabolism 2015; 64 (10) 1272-1278
20 Rasmussen JJ, Selmer C, Østergren PB. , et al. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case–control study. PLoS One 2016; 11 (08) e0161208
21 Rasmussen JJ, Schou M, Selmer C. , et al. Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. Clin Endocrinol (Oxf) 2017; 87 (03) 249-256
22 Rasmussen JJ, Schou M, Madsen PL. , et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma?. J Hypertens 2017; 36 (02) 277-285
23 Bhasin S, Woodhouse L, Casaburi R. , et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281 (06) E1172-E1181
24 Hemker HC, Giesen P, Al Dieri R. , et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
25 Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008; 99 (04) 767-773
26 Anderson RA, Ludlam CA, Wu FC. Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995; 74 (02) 693-697
27 Brady JN, Notley C, Cameron C, Lillicrap D. Androgen effects on factor IX expression: in-vitro and in-vivo studies in mice. Br J Haematol 1998; 101 (02) 273-279
28 Naderi A. Coagulation factor VII is regulated by androgen receptor in breast cancer. Exp Cell Res 2015; 331 (01) 239-250
29 Brodin E, Appelbom H, Osterud B, Hilden I, Petersen LC, Hansen JB. Regulation of thrombin generation by TFPI in plasma without and with heparin. Transl Res 2009; 153 (03) 124-131
30 Agledahl I, Brodin E, Svartberg J, Hansen JB. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels. Thromb Haemost 2009; 101 (03) 471-477
31 van Kesteren PJ, Kooistra T, Lansink M. , et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79 (05) 1029-1033
32 Jin H, Lin J, Fu L. , et al. Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochem Cell Biol 2007; 85 (02) 246-251
33 Jin H, Wang DY, Mei YF. , et al. Mitogen-activated protein kinases pathway is involved in physiological testosterone-induced tissue factor pathway inhibitor expression in endothelial cells. Blood Coagul Fibrinolysis 2010; 21 (05) 420-424
34 Preston FE, Burakowski BK, Porter NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22 (5-6): 543-551
35 Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62 (05) 699-707
36 Sidelmann JJ, Kluft C, Krug AH, Winkler U, Jespersen J, Gram JB. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women. Thromb Haemost 2017; 117 (04) 700-705
37 Martinez C, Suissa S, Rietbrock S. , et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ 2016; 355: i5968
38 Berezovskaya G, Smirnova O, Malev E. , et al. Thrombin generation test for evaluation of antiplatelet treatment in patients with coronary artery disease after percutaneous coronary intervention. Platelets 2017; Apr. 4: 1-7